These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 34021727)

  • 41. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Large-Pore Mesoporous-Silica-Coated Upconversion Nanoparticles as Multifunctional Immunoadjuvants with Ultrahigh Photosensitizer and Antigen Loading Efficiency for Improved Cancer Photodynamic Immunotherapy.
    Ding B; Shao S; Yu C; Teng B; Wang M; Cheng Z; Wong KL; Ma P; Lin J
    Adv Mater; 2018 Dec; 30(52):e1802479. PubMed ID: 30387197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Supramolecular micelles as multifunctional theranostic agents for synergistic photodynamic therapy and hypoxia-activated chemotherapy.
    Huang X; Chen T; Mu N; Lam HW; Sun C; Yue L; Cheng Q; Gao C; Yuan Z; Wang R
    Acta Biomater; 2021 Sep; 131():483-492. PubMed ID: 34265471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
    De Henau O; Rausch M; Winkler D; Campesato LF; Liu C; Cymerman DH; Budhu S; Ghosh A; Pink M; Tchaicha J; Douglas M; Tibbitts T; Sharma S; Proctor J; Kosmider N; White K; Stern H; Soglia J; Adams J; Palombella VJ; McGovern K; Kutok JL; Wolchok JD; Merghoub T
    Nature; 2016 Nov; 539(7629):443-447. PubMed ID: 27828943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Self-adjuvanting photosensitizer nanoparticles for combination photodynamic immunotherapy.
    Zhang G; Wang N; Sun H; Fu X; Zhai S; Cui J
    Biomater Sci; 2021 Oct; 9(20):6940-6949. PubMed ID: 34528658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8
    Zhang Md J; Zhang Md L; Yang Md Y; Liu Md Q; Ma Md H; Huang Md A; Zhao Md Y; Xia Md Z; Liu Md T; Wu Md G
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1533-1546. PubMed ID: 33238192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cell Membrane-Targeting Type I/II Photodynamic Therapy Combination with FSP1 Inhibition for Ferroptosis-Enhanced Photodynamic Immunotherapy.
    Chen J; Duan Z; Deng L; Li L; Li Q; Qu J; Li X; Liu R
    Adv Healthc Mater; 2024 Jun; 13(16):e2304436. PubMed ID: 38335308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
    Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
    EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenic chemotherapy in two mouse colon cancer models.
    Taniura T; Iida Y; Kotani H; Ishitobi K; Tajima Y; Harada M
    Cancer Sci; 2020 Oct; 111(10):3527-3539. PubMed ID: 32816355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multifunctional theranostic agents based on prussian blue nanoparticles for tumor targeted and MRI-guided photodynamic/photothermal combined treatment.
    Lin X; Cao Y; Xue Y; Wu F; Yu F; Wu M; Zhu X
    Nanotechnology; 2020 Mar; 31(13):135101. PubMed ID: 31783383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced cytotoxicity and apoptosis through inhibiting autophagy in metastatic potential colon cancer SW620 cells treated with Chlorin e6 photodynamic therapy.
    Yang K; Niu T; Luo M; Tang L; Kang L
    Photodiagnosis Photodyn Ther; 2018 Dec; 24():332-341. PubMed ID: 30355513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy-resistant lung tumor.
    Mathew AA; Zakkariya ZT; Ashokan A; Manohar M; Keechilat P; Nair SV; Koyakutty M
    Int Immunopharmacol; 2023 Jul; 120():110129. PubMed ID: 37201402
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
    Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
    Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mitochondria-targeted polyprodrug nanoparticles induce mitochondrial stress for immunogenic chemo-photodynamic therapy of ovarian cancer.
    Zhang W; Chen G; Chen Z; Yang X; Zhang B; Wang S; Li Z; Yang Y; Wu Y; Liu Z; Yu Z
    J Control Release; 2024 Jul; 371():470-483. PubMed ID: 38849094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of sanguinarine in regulating immunosuppression in a Lewis lung cancer mouse model.
    Li B; Luo Y; Zhou Y; Wu J; Fang Z; Li Y
    Int Immunopharmacol; 2022 Sep; 110():108964. PubMed ID: 35728305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nano-herb medicine and PDT induced synergistic immunotherapy for colon cancer treatment.
    Wu X; Yang H; Chen X; Gao J; Duan Y; Wei D; Zhang J; Ge K; Liang XJ; Huang Y; Feng S; Zhang R; Chen X; Chang J
    Biomaterials; 2021 Feb; 269():120654. PubMed ID: 33434712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chlorin e6 Conjugated Poly(dopamine) Nanospheres as PDT/PTT Dual-Modal Therapeutic Agents for Enhanced Cancer Therapy.
    Zhang D; Wu M; Zeng Y; Wu L; Wang Q; Han X; Liu X; Liu J
    ACS Appl Mater Interfaces; 2015 Apr; 7(15):8176-87. PubMed ID: 25837008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.